NeoGenomics (NEO) Projected to Release Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $196.9250 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 4:30 PM ET.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The business had revenue of $186.67 million for the quarter, compared to analyst estimates of $184.54 million. The company’s revenue was up 11.3% on a year-over-year basis. On average, analysts expect NeoGenomics to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Price Performance

NASDAQ:NEO opened at $13.89 on Monday. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -18.04 and a beta of 1.74. NeoGenomics has a twelve month low of $4.72 and a twelve month high of $15.57. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $12.19 and a 200-day simple moving average of $10.64.

Insider Transactions at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total transaction of $59,916.03. Following the transaction, the director directly owned 91,422 shares in the company, valued at $1,032,154.38. This represents a 5.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NeoGenomics

Several institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd raised its stake in NeoGenomics by 110.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock worth $35,000 after buying an additional 1,556 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in shares of NeoGenomics in the 4th quarter valued at $39,000. Smartleaf Asset Management LLC raised its position in shares of NeoGenomics by 77.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock worth $42,000 after acquiring an additional 1,515 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of NeoGenomics in the 2nd quarter worth $32,000. Finally, Van ECK Associates Corp lifted its stake in shares of NeoGenomics by 113.8% during the 4th quarter. Van ECK Associates Corp now owns 4,921 shares of the medical research company’s stock worth $58,000 after purchasing an additional 2,619 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on NEO shares. Benchmark raised their price target on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday. TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Leerink Partners raised shares of NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $12.00 to $25.00 in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. Finally, Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, NeoGenomics has an average rating of “Hold” and an average price target of $14.57.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.